Epidermolysis bullosa
MONDO:0006541Epidermolysis bullosa (EB) is a group of genetic skin diseases that cause the skin to blister very easily. Blisters form in response to minor injuries or friction, such as rubbing or scratching. There are four main types of epidermolysis bullosa: dystrophic epidermolysis bullosa Epidermolysis bullosa simplex Junctional epidermolysis bullosa Kindler Syndrome Identifying the exact type can be hard because there are many subtypes of EB. Within each type or subtype, a person may be mildly or severely affected. The disease can range from being a minor inconvenience to completely disabling, and fatal in some cases. Most types of EB are inherited. The inheritance pattern may be autosomal dominant or autosomal recessive. Management involves protecting the skin, reducing friction against the skin, and keeping the skin cool.
Also known as: epidermolysis bullosa, EB
46 clinical trials for this condition and its sub-types, 24 tagged with Epidermolysis bullosa itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Epidermolysis bullosa
-
Inherited epidermolysis bullosa 5 trials · 38 incl. sub-types
4 sub-types
- Epidermolysis bullosa dystrophica 23 trials · 30 incl. sub-types Sub-types →
- Junctional epidermolysis bullosa 6 trials · 8 incl. sub-types Sub-types →
- Epidermolysis bullosa simplex 6 trials Sub-types →
- Kindler syndrome 0 trials Sub-types →
-
Acquired epidermolysis bullosa 3 trials
Most studied deeper sub-types
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Phase 4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Gene therapy skin graft aims to heal wounds in 'Butterfly Children'
Disease control Not yet recruitingThis trial evaluates a gene therapy skin graft called prademagene zamikeracel (pz-cel) for treating wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic condition that causes fragile skin and chronic wounds. The study includes three parts: one…
Phase 4 • Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Phase 1/2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief Not yet recruitingThis Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Phase 3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC